Stock CYTK CYTOKINETICS, INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Delayed Nasdaq
Other stock markets
 03:59:15 2024-07-05 pm EDT 		5-day change 1st Jan Change
55.52 USD +2.05% Intraday chart for Cytokinetics, Incorporated +2.44% -33.52%
Jun. 24 JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating MT
Jun. 17 Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing
Cytokinetics Insider Sold Shares Worth $1,183,391, According to a Recent SEC Filing
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
Cytokinetics Insider Sold Shares Worth $413,106, According to a Recent SEC Filing
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care Stocks Rise Wednesday Afternoon
Sector Update: Health Care
Cytokinetics Says Third Party Dropped Takeover Bid Despite Negotiations; Shares Rise
Cytokinetics Says Third Party Did Not Move Forward with Acquisition After Talks
Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing
Cytokinetics Closes $500 Million Stock Offering
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Rally on NVIDIA Earnings
Top Premarket Decliners
Cytokinetics Prices $500 Million Common Stock Offering
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
Cytokinetics Plans $500 Million Common Stock Offering -- Shares Drop After Hours
Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors
Cytokinetics Q1 Net Loss Narrows, Revenue Declines
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTK Stock
  4. News Cytokinetics, Incorporated
  5. Other languages